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Abstract
Background: Although the use of highly active antiretroviral therapy in HIV positive individuals has proved to be
effective in suppressing the virus to below detection limits of commonly used assays, virological failure associated
with drug resistance is still a major challenge in some settings. The prevalence and effect of pre-treatment resistance
associated variants on virological outcomes may also be underestimated because of reliance on conventional
population sequencing data which excludes minority species. We investigated long term virological outcomes
and the prevalence and pattern of pre-treatment minority drug resistance mutations in individuals initiating
HAART at a local HIV clinic.
Methods: Patient’s records of viral load results and CD4 cell counts from routine treatment monitoring were
used and additional pre-treatment blood samples for Sanger sequencing were obtained. A selection of pre-
treatment samples from individuals who experienced virological failure were evaluated for minority resistance
associated mutations to 1 % prevalence and compared to individuals who achieved viral suppression.
Results: At least one viral load result after 6 months or more of treatment was available for 65 out of 78
individuals followed for up to 33 months. Twenty (30.8 %) of the 65 individuals had detectable viremia and
eight (12.3 %) of them had virological failure (viral load > 1000 RNA copies/ml) after at least 6 months of
HAART. Viral suppression, achieved by month 8 to month 13, was followed by low level viremia in 10.8 % of
patients and virological failure in one patient after month 20. There was potentially reduced activity to Emtricitabine or
Tenofovir in three out of the eight cases in which minority drug resistance associated variants were investigated but
detectable viremia occurred in one of these cases while the activity of Efavirenz was generally reduced in all
the eight cases.
Conclusions: Early viral suppression was followed by low level viremia for some patients which may be an
indication of failure to sustain viral suppression over time. The low level viremia may also be representing
early stages of resistance development. The mutation patterns detected in the minority variants showed
potential reduced drug sensitivity which highlights their potential to dominate after treatment initiation.
Trial registration: Not applicable.
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Background
Highly active antiretroviral therapy (HAART) has resulted
in improved quality of life among people infected with
human immunodeficiency virus (HIV) including reduced
mortality and morbidity rates. However, virological failure
caused by emergence of drug resistant variants still occurs
in some individuals on HAART [1]. Some individuals ex-
perience virological failure after HAART initiation as they
may harbour pre-treatment drug resistant viral species
[2–4]. HIV treatment guidelines from developed countries
recommend drug resistance testing before initiation of
HAART [5, 6]. In developing countries pre-treatment
screening for drug resistant species is however not done
as part of treatment optimization due to limited resources.
Pre-treatment drug resistance data are usually obtained
through conventional population sequencing methods
which do not detect low level viral species with a fre-
quency of less than 20 % [7, 8] and this may underestimate
prevalence figures and the effect that these variants have
on treatment outcomes.
The effect of pre-treatment resistance associated mi-
nority variants on treatment outcomes is a subject of
many studies [7–14]. While some studies have reported
lack of strong association between drug resistance mi-
nority variants and treatment outcomes [9, 10], there is
also strong evidence suggesting otherwise. Patients with
no detectable drug resistance mutations using the
Sanger method but with low level resistance mutations
detected by sensitive methods were shown to have a
more than double increased risk of virological failure
after initiating HAART [11]. Minority drug resistant
species have been shown to reduce the effectiveness of
first line non-nucleoside reverse transcriptase inhibitor
(NNTRI) based regimens which are the widely used regi-
mens in developing countries [12].
Viral load (VL) testing in individuals on HAART is the
method used to detect HIV replication and virological
failure. The measure of a successful HAART program
would be a sustained viral suppression over time in indi-
viduals on the program. The South Africa HIV manage-
ment guidelines recommend VL testing 6 months after
HAART initiation followed by VL testing at 12 months
and every 12 months thereafter [15]. Baseline drug re-
sistance testing is not recommended but pre-treatment
drug resistance prevalence figures of less than 5 % have
been reported in South Africa [16]. We investigated long
term virological outcomes and the pattern of pre-treatment
minority drug resistance mutations in individuals initiating
HAARTat a local HIV clinic.
Methods
Participants
Participants were recruited from Tshwane District
Hospital HIV clinic in Pretoria central, South Africa
between July 2013 and May 2014 after written informed
consent and followed up for at least 12 months and up
to 33 months. Eligible participants were HIV infected
treatment naïve adults with CD4 cell counts < 350 cells/μl
and/or World Health Organization (WHO) clinical stage
3 or stage 4. Participants were initiated on a NNRTI based
regimen consisting of Efavirenz (EFV), Emtricitabine
(FTC) and Tenofovir (TDF).
Sample collection and RNA extraction
Samples were obtained before treatment initiation.
Plasma was isolated from 10 to 15 ml of whole blood
collected in EDTA tubes by centrifugation at 1600 g for
10 min and stored at −70 °C until required for RNA ex-
traction. RNA was extracted from 210 μl of plasma using
the QIAamp Viral RNA Mini kits (Qiagen) and eluted
with 60 μl elution buffer.
Viral load monitoring
Follow up HIV-1 VLs for treatment monitoring were
done after at least 6 months of treatment using Abbott
Real Time HIV-1 test (Abbott laboratories, Illinois,
USA) with a detection limit of 40 RNA copies/ml. Sup-
pression was defined as a VL < 50 RNA copies/ml. Viro-
logical failure was defined as a VL ≥ 1000 RNA copies/
ml after at least 6 months of HAART.
HIV genotypic resistance testing
A previously described method and primers was used
for nucleic acid amplification and sequencing [17].
Superscript III reverse transcriptase enzyme (Life Tech-
nologies Corporation, California, USA) was used for
cDNA synthesis and Platinum Taq enzyme (Life Tech-
nologies Corporation, California, USA) was used for the
polymerase chain reaction (PCR). PCR primers targeted
the protease (PR) gene and the first 300 codons of the
reverse transcriptase (RT) gene (HXB2 nucleotide 2166–
3440). BigDye Terminator V3.1 Cycle Sequencing Ready
Reaction Kit (Applied Biosystems, Foster City, CA, USA)
was used for sequencing reactions with two forward and
two reverse primers and sequencing was done on the
3100 Automatic capillary sequencer (Applied Biosystems,
Foster City, CA, USA). Sequences were edited and assem-
bled on Sequencher V 4.5 (Gene Codes Corporation,
USA). The Stanford HIVdb algorithm Version 7.0. (http://
hivdb.stanford.edu/) was used for subtyping, resistance
mutations interpretation and quality assessment.
HIV deep sequencing
For ultra-deep sequencing (UDS) amplicons obtained
from pre-treatment samples from four individuals who
experienced virological failure were sent to Inqaba Bio-
technical industries in Pretoria South Africa for sequen-
cing up to 1 % prevalence. Additional samples from
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three individuals who virally suppressed and one sample
from an individual who experienced low level viremia
were also deep sequenced to provide comparison.
Briefly, cDNA samples were fragmented using an
ultrasonication approach and the resulting fragments
were purified and size selected, end repaired and an illu-
mina specific adapter sequence ligated. Following quan-
tification, the samples were individually indexed and a
second size selection step was performed using AMPure
XP Beads. Libraries were quality controlled on a DNA
chip (Agilent 2100 Bioanalyzer) and then sequenced on
illumina’s MiSeq platform, using a MiSeq v3 kit accord-
ing to the manufacturer’s protocol. Fifty (50) Mb of data
(2 × 300bp long paired end reads) were produced for
each sample. This was followed by HIV sequence ana-
lysis and quality check, genotyping and drug resistance
interpretations using Deepchek 1.4 HIV analysis soft-
ware. A minimum of 461 sequences was required for
99 % confidence at 1 % threshold and a Q30 score meas-
ure was applied for basecalling.
Pre-treatment drug resistance determination
Pre-treatment drug resistance was defined as identifica-
tion of a mutation that is known to cause a reduced
susceptibility to at least one prescribed drug.
Adherence monitoring
Adherence was monitored using a combination of mea-
sures including checking for missed clinic visits, partici-
pant interviews and investigating reasons for which
participants had been sent for counselling sessions.
Statistical analysis
Differences between mean CD4 cell counts were calcu-
lated in excel using the t-test Two sample assuming
equal variances.
Results
Enrolled participants characteristics and follow up
A total of 78 participants were recruited into the study.
At least one follow up viral load result was available for
65 participants. Follow up viral loads were not available
for 13 participants (16.6 %) due to loss to follow up.
Participant characteristics are shown in Table 1.
Treatment initiation to first viral load monitoring
After treatment initiation, participants came for the first
viral load monitoring at different time points (Fig. 1).
Virological outcomes
There were 20 participants (30.8 %) with detectable
viremia at some point after at least 6 months of HAART
(Fig. 2). Virological failure (>1000 RNA copies/ml) was
detected in eight participants (12.3 %) with the following
identification codes (IDs): L013, L029, L031, L037, L039,
L054, L064 and L069 while the rest of the participants
had low level viral loads < 1 000 RNA copies/ml. Viro-
logical failure occurred at 6–12 months after HAART
initiation in six individuals (accounting for 9.2 % overall
and 75 % in virological failure group) while virological
failure occurred at 22 months in one individual (L039)
who had initially achieved viral suppression.
There were eight participants (12.3 %), L022, L038,
L039, L049, L058, L061, L063 and L067, who had ini-
tially suppressed the virus to below detection limits by
month 8 to month 13 followed by detectable viremia at
month 20 or after in all cases. The detected VLs after
initial suppression were < 1 000 RNA copies/ml except
for L039 with a VL of 21 646 RNA copies/ml. Subse-
quent viral load results after the initial rebound were
available for two of these individuals, L038 and L039,
and were done 10 and 3 months later respectively. The
detectable viremia was shown to persist in both cases.
Immunological outcomes of participants with detectable
viremia
There were no differences in mean baseline CD4 cell
counts between the group that managed to achieve viral
Table 1 Enrolled participants characteristics
Participants (n = 78)
Gender
Males (%) 26 (33.3)








Mean CD4 count 192
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suppression and the groups with detectable viremia
(Table 2). The same pattern was observed in CD4 cell
counts done after 6–12 months of treatment. How-
ever, there was a significant difference between mean
baseline CD4 cell counts and mean CD4 cell counts
at 6–12 months after treatment initiation for the vir-
ally suppressed group and the low level viremia
group. The virological failure group did not achieve a
significant change in mean CD4 cell counts between








































First post HAART initiation viral load test (Month after HAART initiation)
Fig. 1 Time of first viral load testing after HAART initiation. The majority of participants (46) had at least one viral load (VL) test done by month 12
after HAART initiation. The first viral load test was done after month 12 in 15 (24.5 %) individuals. No viral load tests had been done by month 30
in 13 individuals
Fig. 2 Participants with detectable viremia after at least 12 months of HAART. Virological failure generally occurred within the first 12 months of
treatment initiation (red squares) while detectable viremia after initial suppression was shown to occur after month 20 of treatment (orange squares)
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virological failure were < 500 cells/μl (range = 21–441
cells/ μl) for six out of the eight participants while
participant L013 who was virally suppressed at some
point had a CD4 cell count > 500 cells/μl (Fig. 2). Of
the eight participants who initially suppressed the
virus but later had detectable viremia, three had CD4
cell counts < 350 cells/μl at the time of viral suppres-
sion, while four participants had CD4 cell counts >
350 (range = 427–746 cells/μl) (Fig. 2).
Baseline minority resistance mutations in participants
with detectable viremia
Detection of baseline minority resistance associated mu-
tations using ultra deep sequencing to 1 % threshold was
done for eight participants. The coverage and basis for
excluding some mutations from analysis is shown in
Fig. 3 and Additional file 1: Figure S1. Of these eight
participants: four had virological failure (>1000 RNA
copies/ml), one had low level viremia < 1 000 RNA cop-
ies/ml and three had suppressed viremia (<50 RNA cop-
ies/ml) after at least 6 months of HAART. The
mutations list and patterns are shown in Table 3.
Impact of treatment efficacy of initiated drugs
NRTI drugs TDF or FTC had potentially reduced activity
in three out of the eight cases in which minority drug re-
sistance associated variants were detected but detectable
viremia occurred in one of these cases. The activity of
EFV was reduced in all the eight cases ranging from low
level resistance (two cases) to high level resistance (1
case). Taken together, the pattern of minority variants
detected showed potentially reduced EFV treatment effi-
cacy and were generally susceptible to the NRTI drugs
TDF and FTC at 1 % prevalence.
Discussion
The goal of HIV antiretroviral therapy is to achieve sus-
tained viral suppression in individuals on treatment.
Virological failure due to development of drug resistance
is still a challenge for many HIV treatment programmes
in developing countries due to lack of resources for ef-
fective treatment monitoring and treatment optimization
among other challenges. Furthermore, the effect of pre-
treatment resistance associated minority variants on
virological outcomes is still not well understood and
largely underestimated because of reliance on conven-
tional population sequencing data which do not include
minority species. In this long term follow up study, base-
line samples showed a high prevalence of pre-treatment
resistance associated minority variants although their
clinical relevance requires further study. There was high
prevalence (30.8 %) of detectable viremia of any kind
after at least 6 months of HAART and in 40 % of these
cases detectable viremia occurred after previous viral
suppression to below detection limits.
Virological failure occurred in 12.3 % of the partici-
pants compared to an overall 15 % virological failure rate
(range 0–43 %) calculated from 19 studies done in sub-
Saharan Africa countries [18]. However the duration of
treatment at time of failure detection was not mentioned
for most of these studies. We detected virological failure
at month 6 to 12 after initiation of HAART except
where virological failure was detected after previous viral
suppression. Viral load testing at month 6 and month 12
after HAART initiation, which is recommended in South
African public health institutions caring for HIV positive
patients, seems adequate to detect early virological fail-
ure as was shown in our participants. However, up to
23.1 % of participants as indicated in Fig. 1 had their
first post HAART initiation viral load after more than
12 months which may affect the detection of early viro-
logical failure. South Africa HIV management guidelines
[15] use a cut off value of VL > 1000 RNA copies/ml to
define virological failure, however HIV treatment guide-
lines from some developed countries are more stringent
and define virological failure as confirmed VL > 50 RNA
Table 2 Comparison of mean CD4 cell counts: Intergroup and intragroup comparison of mean CD4 cell counts for the virally










(α = 5 %)
Baseline CD4 cell count (cells/μl) n = 45, Mean = 199 n = 8, Mean = 183 0.74
n = 45, Mean = 199 n = 12, Mean = 181 0.66
n = 45, Mean = 199 n = 20, Mean = 182 0.61
n = 8, Mean = 183 n = 12, Mean = 181 0.97
CD4 cell count @ 6–12 months
after treatment initiation (cells/μl)
n = 18, Mean = 387 n = 8, Mean = 250 0.18
n = 18, Mean = 387 n = 9, Mean = 438 0.58
n = 18, Mean = 387 n = 17, Mean = 350 0.64
n = 8, Mean = 250 n = 9, Mean = 438 0.07
P-value (α = 5 %) 0.0001 0.47 0.001 0.01
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copies/ ml [5, 6]. Using this criterion, our frequency of
virological failure would increase by more than 50 %
from 12.3 to 30.8 %.
We noted that viral suppression had been achieved by
month 8 to month 13 and viral rebound occurred after
month 20 in a subset of individuals indicating failure to
sustain viral suppression over time. Although the
rebound resulted in low level viremia ranging from 83
RNA copies/ml to 579 RNA copies/ml in seven of the
cases, detection of low level viremia after previous viral
suppression should be monitored as these detections
may be early stages of resistance development.
The association of pre-treatment minority drug
resistance associated HIV variants of < 1 % frequency or
greater with increased risk of virological failure for indi-
viduals on NNRTI based regimens has been highlighted
[12]. The mutation patterns detected in the minority
variants showed potentially reduced sensitivity to EFV
and to a lesser extent TDF and FTC which highlights
their potential to dominate after treatment initiation.
However, the comparison of the pre-treatment pattern
of minority variants detected between the virological
failure group and the suppressed group did not show a
specific pattern associated with virological failure at this
stage indicating that other factors might be involved.
Factors such as mutation linkages and mutational loads
also need to be investigated. A single TAM D67E was
found to be highly prevalent but TDF-based regimens
have been shown to be effective in the presence of other
single TAMs such as M41L at baseline [19]. Pre-
treatment minority TAMs M41L and K70R have been
reported in other studies [20] including multiple TAMs
of up to six in another study [13].
Pre-treatment HIV drug resistance has been shown to
increase regimen switches in developing countries [2]
which results in increased treatment costs and
Fig. 3 Deep sequencing coverage of analysed samples. a Showing L013 (virological failure) and (b) showing L001 (virally suppressed). Mutations
were excluded from analysis for any of the following: noisy mutations filtering, coverage filtering, forward/reverse unbalanced frequency and
forward/reverse unbalanced coverage. Additional file 1: Figure S1 shows the rest of the samples. C – E (virological failure, L031, L054 and L064
respectively) and F – H (detectable viremia, L009 and virally suppressed L074 and L075 respectively)
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exhaustion of treatment options. Recent studies have
also demonstrated strong association between low level
viremia of 200–499 RNA copies/ml with virological fail-
ure [21] while some studies have associated virological
failure with lower levels of less than 50 copies per ml
[22] after a follow up period of up to 2 years. This com-
pares with our results where viremia after initial sup-
pression was detected at month 20 and after and shown
to persist on subsequent testing. Low level viremia may
also be viewed in light of the correlation between viral
persistence and the viral reservoir size which may re-
quire several years of HAART to reduce [23, 24].
We noted that 43 % of individuals who experienced
low level viral rebound after initially suppressing the
virus generally had poor immunological outcomes with a
CD4 cell count < 350 cells/μl after more than 6 months
of HAART. The same poor immunological outcome pat-
tern was observed in individuals who experienced viro-
logical failure where 75 % of them had a CD4 cell count
< 350 cells/μl. However CD4 cell count monitoring in
isolation has been shown to be a poor marker for treat-
ment failure [25, 26] and in our case we had a minority
of individuals with CD4 cell counts > 500 experiencing
virological failure or viral rebound.
The study has a number of limitations in particular
the absence of resistance data at the time of virological
failure. Additional samples taken at the time of routine
viral load testing were not always available since the re-
searchers were not part of the routine patient care
personnel at the clinic where participants accessed care.
The small number of samples that were deep sequenced
also limited the information and conclusions that could
be derived from this data. The data obtained however
provide a basis for further investigation using larger
sample sizes and comparison of baseline minority muta-
tions with sequences dominating at time of failure. We
also relied on self-reported information on treatment ad-
herence to monitor participant’s treatment adherence
levels. Poor adherence to treatment may have been the
cause of virological failure in some individuals given that
there was a high loss to follow up of 20 % in our cohort.
Many studies have shown that poor treatment adherence
is associated with virological failure in resource limited
settings [27–30] and that an adherence of at least 95 %
Table 3 Baseline minority resistance mutations detected by ultra-deep sequencing
ID Virological outcome
after at least 6 months
of HAART
Genotype Baseline resistance mutations (% prevalence) Drug activity of initiated
regimen (Based on drug
resistance mutation
surveillance list [31])
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L054 Virological failure C A62V (1.51)
D67E (1.16)
F77L (1.52)
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in individuals with minority variants significantly lowers
the risk of virological failure [12].
Conclusions
While the development of low level viremia or viro-
logical failure after previously suppressing the virus that
we noticed in a subgroup of our participants could be
due to viral persistence emanating from established viral
reservoirs, there is need to establish if such occurrences
might be due to resistant minority variants beginning to
take over and dominate following suppression of the
treatment sensitive population. These data therefore
highlight the need for a better understanding of the role
played by pre-treatment HIV drug resistance associated
minority variants under various clinical settings.
Additional file
Additional file 1: Figure S1. Deep sequencing coverage. C – E shows
sequencing coverage for samples with virologicalfailure (L031, L054 and
L064 respectively), F shows coverage for a sample with detectable
viremia (L009)and G and H show coverage for virally suppressed samples
(L074 and L075 respectively). Mutations wereexcluded from analysis for
any of the following: noisy mutations filtering, coverage filtering, forward/
reverse unbalanced frequency and forward/reverse unbalanced coverage.
(DOCX 1189 kb)
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